Scientific deep-dive

Cancer Risk in People Without Diabetes

A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Most studies of these drugs and cancer are done in people with diabetes, where the comparison drug is itself a marker of how sick someone is. This one was done in obese adults without diabetes, and found 41% lower incidence of obesity-associated cancers.[1] It also has a median follow-up of two years, which is the problem.

What was found

After propensity score matching, GLP-1 users had a significantly lower incidence of obesity-associated cancers, with a hazard ratio of 0.59 (95% CI 0.53 to 0.67). Participants had a mean age of 47.2. An inverse probability of treatment weighting analysis confirmed the finding, and it held across subgroups, with one exception discussed below.[1]

The population is what this study adds. We have written about a study reporting 91% lower breast cancer mortality that evaporated against a fair comparator, because insulin users are sicker than GLP-1 users by definition. Studying people without diabetes removes that specific problem.

Two years is not long enough to answer this

A cancer diagnosed within two years of starting a drug was, in most cases, already there when the drug started.

Solid tumors develop over years to decades. A median follow-up of two years, with an interquartile range of one to two, captures diagnoses rather than causation. The authors describe the result as a short-term incidence finding and call for prospective trials to confirm causality.[1]

This is the same structural limitation we found in the randomized evidence: a systematic review in the Annals of Internal Medicine concluded that any effect of these drugs on obesity-related cancers may be little or none, while noting the included trials were not designed to evaluate cancer outcomes and had short follow-up. That is in the randomized answer.

There is a mechanism that could produce this result with no anti-cancer effect at all. People who start a new prescription drug enter the health system: appointments, bloodwork, imaging for other reasons. Detection patterns differ between people receiving active treatment and people who are not, in both directions, and a two-year window is exactly where a detection difference would dominate a biological one.

The subgroup that did not follow the pattern

The association held in every subgroup examined except Black patients.[1] The careful reading of that finding is not a biological one.

We covered the same shape in who responds in the real world, where a real-world cohort found weight-loss outcomes differing by race while 64 randomized trials found none. The explanation there applies here: trials equalize access, continuity and follow-up, and ordinary care does not. A benefit that requires sustained treatment will appear smaller in any group whose treatment is more often interrupted. A benefit measured by diagnosis also depends on who receives screening.

Reading a subgroup difference in an observational cancer study as a difference in how bodies respond, rather than in how care is delivered, would be unsupported by the randomized evidence and would mislocate the problem.

Where this leaves the question

  • The direction is consistent across cohorts, drug classes and now a nondiabetic population, which carries some weight.
  • The magnitude is not. A 41% reduction is large enough to trigger the rule we set out in when a hazard ratio is too good: in observational data, big effects usually describe who was prescribed the drug.
  • The mechanism is plausible. Obesity is an established driver of the thirteen cancer types usually classed as obesity-associated, and these drugs reduce obesity.
  • The follow-up cannot support the claim. Two years is too short to answer this question, whatever result it shows.

Nothing here is a reason to take or avoid one of these drugs on cancer grounds, and no GLP-1 is indicated for cancer prevention anywhere.

Frequently Asked Questions

A large propensity-matched study found 41% lower short-term incidence of obesity-associated cancers, with a hazard ratio of 0.59. The median follow-up was two years, which is far too short to establish that a drug prevented a cancer.
Because most cancer studies in this class compare against other diabetes drugs, and drugs like insulin mark more advanced disease. Comparing against them measures how sick each group already was. A nondiabetic population removes that particular confound.
Solid tumors develop over years to decades, so a cancer diagnosed within two years of starting a drug was, in most cases, present beforehand. The authors themselves describe this as a short-term incidence finding and call for prospective trials.
The association held in every subgroup except Black patients. The supported reading is about care, not biology. A benefit requiring sustained treatment appears smaller in any group whose treatment is more often interrupted, and a benefit measured by diagnosis depends on who receives screening.
No. There is no such indication anywhere, the follow-up in this study cannot support a causal claim, and randomized evidence to date suggests little or no effect either way.

References

  1. 1.Hsu AH, Ramirez PT, Chang YH, et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults Annals of Oncology. 2026. PMID: 42252247.

GLP-1s and Cancer: What the Cohorts Actually Show

One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.

7 min read

GLP-1s in People Being Treated for Cancer

Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.

5 min read

GLP-1s and Cancer: The Randomized Answer

Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.

6 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show

GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.

11 min read

Compounded GLP-1s and the Adverse Event Reports

A FAERS study found more adverse event reports for compounded GLP-1s. Reports are voluntary and there is no denominator, but one finding survives that critique: preparation and prescribing errors were reported more often for compounded products, while dosing errors were reported less often.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

9.1

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

From $59/mo + membership

Get started →
Read full review →
8.5

Gala

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →